Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.

Eum S, Lee AM, Bishop JR.

Dialogues Clin Neurosci. 2016 Sep;18(3):323-337.

2.

Where Failure Is Not an Option -Personalized Medicine in Astronauts.

Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R.

PLoS One. 2015 Oct 21;10(10):e0140764. doi: 10.1371/journal.pone.0140764. eCollection 2015.

3.

Pharmacogenetics and outcome with antipsychotic drugs.

Pouget JG, Shams TA, Tiwari AK, Müller DJ.

Dialogues Clin Neurosci. 2014 Dec;16(4):555-66. Review.

4.

Effect of smoking on the pharmacokinetics of inhaled loxapine.

Takahashi LH, Huie K, Spyker DA, Fishman RS, Cassella JV.

Ther Drug Monit. 2014 Oct;36(5):618-23. doi: 10.1097/FTD.0000000000000048.

5.

Significance of the 13C-caffeine breath test for patients with cirrhosis.

Konstantinou D, Margariti E, Hadziyannis E, Pectasides D, Papatheodoridis GV.

Ann Gastroenterol. 2014;27(1):53-59.

6.

Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae.

Fasullo M, Smith A, Egner P, Cera C.

Mutat Res Genet Toxicol Environ Mutagen. 2014 Feb;761:18-26. doi: 10.1016/j.mrgentox.2014.01.009. Epub 2014 Jan 25.

7.

Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism.

Li QY, Guo ZZ, Deng X, Xu LM, Gao YQ, Zhang W, Wang XS, Xue DY, Lu YY, Liu P, Su SB.

Evid Based Complement Alternat Med. 2013;2013:302131. doi: 10.1155/2013/302131. Epub 2013 Oct 24.

8.

Current status on genome-metabolome-wide associations: an opportunity in nutrition research.

Montoliu I, Genick U, Ledda M, Collino S, Martin FP, le Coutre J, Rezzi S.

Genes Nutr. 2013 Jan;8(1):19-27. doi: 10.1007/s12263-012-0313-7. Epub 2012 Oct 16.

9.

Reduced neurobehavioral impairment from sleep deprivation in older adults: contribution of adenosinergic mechanisms.

Landolt HP, Rétey JV, Adam M.

Front Neurol. 2012 Apr 27;3:62. doi: 10.3389/fneur.2012.00062. eCollection 2012.

10.

Sex-dependent modulation of treatment response.

Rubinow DR, Moore M.

Dialogues Clin Neurosci. 2004 Mar;6(1):39-51.

11.

PharmGKB summary: very important pharmacogene information for CYP1A2.

Thorn CF, Aklillu E, Klein TE, Altman RB.

Pharmacogenet Genomics. 2012 Jan;22(1):73-7. doi: 10.1097/FPC.0b013e32834c6efd. No abstract available.

12.

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM.

Front Pharmacol. 2010 Nov 2;1:129. doi: 10.3389/fphar.2010.00129. eCollection 2010.

13.

Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM.

Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, Nolte IM; kConFab Investigators, Vink JM, Rawal R, Mangino M, Teumer A, Keers JC, Verwoert G, Baumeister S, Biffar R, Petersmann A, Dahmen N, Doering A, Isaacs A, Broer L, Wray NR, Montgomery GW, Levy D, Psaty BM, Gudnason V, Chakravarti A, Sulem P, Gudbjartsson DF, Kiemeney LA, Thorsteinsdottir U, Stefansson K, van Rooij FJ, Aulchenko YS, Hottenga JJ, Rivadeneira FR, Hofman A, Uitterlinden AG, Hammond CJ, Shin SY, Ikram A, Witteman JC, Janssens AC, Snieder H, Tiemeier H, Wolfenbuttel BH, Oostra BA, Heath AC, Wichmann E, Spector TD, Grabe HJ, Boomsma DI, Martin NG, van Duijn CM.

Mol Psychiatry. 2012 Nov;17(11):1116-29. doi: 10.1038/mp.2011.101. Epub 2011 Aug 30.

14.

Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study.

Tao L, Xiang YB, Chan KK, Wang R, Gao YT, Yu MC, Yuan JM.

Int J Cancer. 2012 Mar 1;130(5):1174-83. doi: 10.1002/ijc.26121. Epub 2011 Jun 21.

15.

The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine.

Haslemo T, Refsum H, Molden E.

Br J Clin Pharmacol. 2011 Apr;71(4):611-5. doi: 10.1111/j.1365-2125.2010.03880.x.

16.

Caffeine, selected metabolic gene variants, and risk for neural tube defects.

Schmidt RJ, Romitti PA, Burns TL, Murray JC, Browne ML, Druschel CM, Olney RS; National Birth Defects Prevention Study.

Birth Defects Res A Clin Mol Teratol. 2010 Jul;88(7):560-9. doi: 10.1002/bdra.20681.

17.

Genetics of caffeine consumption and responses to caffeine.

Yang A, Palmer AA, de Wit H.

Psychopharmacology (Berl). 2010 Aug;211(3):245-57. doi: 10.1007/s00213-010-1900-1. Epub 2010 Jun 9. Review.

19.

Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E.

AAPS J. 2009 Sep;11(3):481-94. doi: 10.1208/s12248-009-9127-y. Epub 2009 Jul 10. Review.

20.

Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study.

CARE Study Group.

BMJ. 2008 Nov 3;337:a2332. doi: 10.1136/bmj.a2332. Erratum in: BMJ. 2010;340. doi: 10.1136/bmj.c2331.

Supplemental Content

Support Center